cirrhosis

Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

Selvigaltin (GB1211) is a Gal-3 inhibitor with potential anticancer activity. Selvigaltin is used in the study of cirrhosis and cancer.

Cefetamet sodium (Ro 15-8074 001) is an orally available cephalosporin antibiotic with antimicrobial activity and is used to study cirrhosis of the liver and lung infections.

Torsemide (AC-4464) is an anilinopyridine sulfonylurea belonging to the class of loop diuretics. Torsemide has a prolonged duration of action compared to other loop diuretics, is extensively protein bound in plasma and has a relatively long half-life.

L-Ornithine L-aspartate (Ornithine Aspartate) lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis.

Sinapinic Acid (Synapoic acid) protects the rat liver from CCl4-induced inflammation, most likely by acting as a free radical scavenger and modulator of NF-κB p65 activation and proinflammatory cytokine expression. Sinapic acid with antioxidant role protects cardiac cells and its functions from I R induced oxidative stress. Sinapic acid is a potentially useful agent for the protection against liver fibrosis and cirrhosis. Sinapic acid prevents the alterations in the levels of lipids and lipoproteins by virtue of its anti-lipidaemic effect in isoproterenol induced myocardial infarcted rats. Sinapic acid ameliorates hyperglycemia through PLC-PKC signals to enhance the glucose utilization in diabetic rats.

Malotilate (Kantec) is a medicine used for the therapy of liver cirrhosis.

Tauroursodeoxycholate sodium (TUDC) is an endoplasmic reticulum (ER) stress inhibitor, used for the treatment of gallstones and liver cirrhosis.

CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.

Odevixibat (A4250) is an effective, selective and orally active ileal bile acid transporter inhibitor. Odevixibat has the potential for the treatment of primary biliary cirrhosis. Odevixibat reduces cholestatic liver and bile duct injury in mice model.

Satavaptan is a vasopressin V2 receptor antagonist. Satavaptan improves the control of ascites in cirrhosis.

Polythiazide (NSC-108161, P-2525) is used to treat fluid retention (edema) caused by a variety of causes, including congestive heart failure, severe liver disease (cirrhosis), kidney disease, or steroid or hormonal medication.

Sodium Glucuronic Acid (4-FLUOROCINNAMONITRILE) is used in the treatment of hepatitis and liver cirrhosis.

Taurohyocholic acid (THCA) is a taurine-conjugated form of the porcine-specific primary bile acid hyocholic acid .1THCA inhibits precipitation of cholesterol crystals by stabilizing cholesterol in the liquid-crystalline phase.2It prevents cholestasis and cellular necrosis induced by taurolithocholic acid in isolated rat livers.3THCA levels are increased in the urine of patients with hepatitis B-induced cirrhosis.4

Paromomycin (Sulfate Salt) is an aminoglycoside that is active against Gram-negative and many Gram-positive bacteria as well as some protozoa and cestodes. Paromomycin in combination with sodium stibogluconate has proven to be effective in African and Indian VL (visceral leishmaniasis) and improves survival in African VL[3]. PS (Paromomycin Sulfate) is effective for elimination of B. coli without hematological side effects[4]. The activity of phosphoglucose isomerase was slightly inhibited by 10(-3) M paromomycin sulfate while those of hexokinase, phosphofructokinase and glucose-6-phosphate dehydrogenase were not inhibited[5]. In addition, with regard to correlation of endotoxemia with renal impairment, endogenous creatinine clearance and p-aminohippurate clearance were significantly improved (P less than 0.02) in those patients whose endotoxemia disappeared on paromomycin sulfate administration. Paromomycin sulfate seems to be effective in the prevention of endotoxemia and the associated renal impairment in cirrhosis in man[6]. Significantly higher frequencies of resistance to paromomycin, kanamycin, neomycin and tobramycin were observed in S. aureus isolates from PS (paromomycin supplemented) birds. Paromomycin supplementation resulted in resistance to aminoglycosides in bacteria of PS turkeys. Co-selection for resistance to other antimicrobial agents was observed in E. coli isolates[7].

Etozolin HCl is a safe and effective diuretic agent in the treatment of acute cardiac failure. In isolated rings of guinea-pig aorta not responding to acetylcholine, the diuretic dexetozoline did not influence basal vascular tone but inhibited noradrenaline- and histamine-induced contractions. Dexetozoline has a very high bioavailability after oral administration and is fairly lipohilic. The half-life of etozolin is 2.5 h. Dexetozoline accumulates in cirrhosis.

BMS-986339 is an orally active, potent FXR agonist that engages His298 and ASN287 residues via H-bond formation. It is employed in research on primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH) due to its anti-fibrosis properties.

BI‑3231 is a selective and potent inhibitor of hydroxysteroid 17ß-dehydrogenase 13 HSD17B13, inhibiting hHSD17B13 and mHSD17B13.BI-3231 can be used for the study of alcohol-associated liver injury, fibrosis and cirrhosis.

S-Adenosyl-L-methionine (Ademetionine) is an intermediate metabolite of methionine,for treatment of primary biliary cirrhosis and major depressive disorder.

Silybin is a flavonoid from Silybum that inhibits P-glycoprotein-assisted extracellular efflux, inhibits cytochrome P450 enzymes, has the advantage of being well-tolerated, can be used as an adjunctive treatment for hepatotoxicity and chronic hepatitis and cirrhosis, and has antioxidant and anti-inflammatory activity in cosmetic applications, as well as being capable of blocking the MCT8 transporter protein.

Simtuzumab is a monoclonal antibody against lysyl oxidase-like protein 2 (LOXL2). Simtuzumab can be used to treat primary sclerosing cholangitis (PSC) and is not effective in patients with bridging fibrosis or compensatory cirrhosis caused by non-alcoholic steatohepatitis.

Invopressin (Compound 42), a vasopressin V1A receptor partial agonist (EC50: 1.0 nM), is utilized in research related to cirrhosis conditions such as bacterial peritonitis, HRS2, and refractory ascites [1].

Taurohyocholic acid (THCA), a taurine-conjugated form of porcine-specific primary bile acid hyocholic acid, inhibits cholesterol crystal precipitation by stabilizing cholesterol in the liquid-crystalline phase and prevents cholestasis and cellular necrosis in isolated rat livers induced by taurolithocholic acid. Additionally, THCA levels rise in the urine of patients with hepatitis B-induced cirrhosis.

HSD17B13-IN-22 (Compound 18.03), a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), is utilized in studying various liver diseases including hepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma [1].